Scientific corner

Evidence-based clinical practice guidelines for inflammatory bowel disease

Katsuyoshi Matsuoka 1Taku Kobayashi 1Fumiaki Ueno 2 3Toshiyuki Matsui 1Fumihito Hirai 1Nagamu Inoue 1Jun Kato 1Kenji Kobayashi 1Kiyonori Kobayashi 1Kazutaka Koganei 1Reiko Kunisaki 1Satoshi Motoya 1Masakazu Nagahori 1Hiroshi Nakase 1Fumio Omata 1Masayuki Saruta 1Toshiaki Watanabe 1Toshiaki Tanaka 1Takanori Kanai 1Yoshinori Noguchi 1Ken-Ichi Takahashi 1Kenji Watanabe 1Toshifumi Hibi 1Yasuo Suzuki 1Mamoru Watanabe 1Kentaro Sugano 1Tooru Shimosegawa 1 , J Gastroenterol. 2018 Mar;53(3):305-353.

Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn’s disease (CD) in Japanese. A total of 59 clinical questions for 9 categories (1. clinical features of IBD; 2. diagnosis; 3. general consideration in treatment; 4. therapeutic interventions for IBD; 5. treatment of UC; 6. treatment of CD; 7. extraintestinal complications; 8. cancer surveillance; 9. IBD in special situation) were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases. The guidelines were developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Recommendations were made using Delphi rounds. This English version was produced and edited based on the existing updated guidelines in Japanese.

Evidence-based clinical practice guidelines for inflammatory bowel disease – PMC (

Contact UsFor more information

Contact Us